Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study formulated and evaluated a herbal shampoo with natural ingredients, finding it to be a viable alternative for hair cleansing and maintenance without adverse effects, suggesting it could reduce reliance on shampoos with synthetic chemicals.

This study found that a specific fragment of AIMP1 secreted by hair follicle stem cells can stimulate dermal papilla cells and promote hair regrowth.

This study reports the crystallization of the human androgen receptor's ligand-binding domain with nonsteroidal ligands, which may aid in understanding the differences in binding compared to steroidal ligands.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This literature review highlights a potential but uncertain link between GLP-1 receptor agonist therapy for type 2 diabetes and obesity and hair loss, with variations among different medications.

In this mouse study, researchers found that orally administered low-molecular-weight fish collagen peptides significantly improved hair regrowth by both enhancing growth-promoting pathways and reducing inhibitory mechanisms.

This study reports conflicting evidence on whether GLP-1 receptor agonists are associated with various forms of alopecia, suggesting dermatology practitioners should consider monitoring and counseling patients using these medications.

This review summarizes recent research into the effects of GLP-1 receptor agonists on skin processes, noting potential benefits for wound healing but also potential cosmetic concerns like facial fat loss and decreased collagen, highlighting the need for more clinical studies to clarify their dermatological impact.

This study evaluated a novel synthetic cell-penetrating peptide, DualPep-ALO, finding it promotes hair growth by enhancing follicle cell proliferation, activating regenerative pathways, and reducing inflammation and oxidative stress in vitro and ex vivo, suggesting a promising new topical treatment for hair loss that rivals minoxidil.

This research reports that KCV and its palmitoylated derivatives show strong effectiveness in strengthening hair proteins, indicating their potential for use in advanced hair care products.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This study introduced ElixirSeeker2, a computational framework for designing anti-aging peptides, and found that some newly identified peptides significantly delayed cellular senescence and enhanced cellular and locomotor functions in aged Caenorhabditis elegans.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

In a murine model of androgenetic alopecia, this study found that the newly designed IGF-1 biomimetic peptide Ac-GFFY-IGF led to faster and superior hair regrowth compared to minoxidil, suggesting potential for improved human therapies.

This literature review on neurocosmetics found that both nature-derived peptides and synthetic molecules can improve skin concerns like aging and pigmentation, while also promoting emotional well-being; however, gaps in long-term efficacy and personalized approaches remain.

This study found that microspicule cosmetics with low-molecular-weight peptide complexes significantly improved skin whitening, pore condition, and skin barrier function over four weeks compared to a non-microspicule formulation.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

VIP reduces hair pigmentation by decreasing melanin production.

This study suggests that APC collagen peptides may accelerate hair growth and promote overall hair health by enhancing cellular proliferation and activating specific signaling pathways in human and mouse models.

TAT-GILZ peptide promotes hair growth by boosting stem cell activity.

The authors will correct the table to show the right antibody information.

This study found that AP collagen peptides can promote hair growth by supporting the health of hair follicle cells, as they stimulate cell proliferation, counteract apoptosis, and enhance antioxidant enzyme expression, suggesting potential as a treatment for hair loss.

This study found that a new transdermal drug delivery system using globefish skin collagen peptides and dissolving microneedles effectively promoted hair regrowth in mice with androgenetic alopecia by reducing inflammation and enhancing vascularization.

In this study, FOL-026, a peptide based on osteopontin, was shown to promote angiogenesis and stimulate vascular cell proliferation and migration through neuropilin-1, similar to VEGF, suggesting potential therapeutic applications in vascular repair and angiogenesis-related conditions.

In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.

This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.